Mr. Qiyu Chen, aged 47, was appointed as a non-executive director of the Company on 15 January 2013 and the chairman of the board of directors on 8 December 2018. Mr. Chen joined Fosun Pharma in April 1994 and has been working there ever since. He has been appointed as a director and the chairman of Fosun Pharma in May 2005 and June 2010, respectively. He is currently an executive director of Fosun International since July 2015, and he has been a co-president from March 2017 to February 2020 and a co-chief executive officer since February 2020. Mr. Chen has been a non-executive director and a vice chairman of Sinopharm Group Co. Ltd. (Stock Exchange stock code: 01099) since May 2010 and September 2014, respectively, a director of Beijing Sanyuan Foods Co., Ltd. (Shanghai Stock Exchange stock code: 600429) since March 2015, and a non-executive director of Babytree Group (Stock Exchange stock code: 01761) since June 2018, respectively. In addition, Mr. Chen holds directorships in various companies invested by Fosun International and its affiliated companies and has served as the co-chairman of New Frontier Health Corporation (listed on the New York Stock Exchange, stock code: NFH) since December 2019. Mr. Chen also served as a director of Maxigen Biotech Inc. (Taiwan Stock Exchange stock code: 01783) from December 2015 to November 2017 and a director of Dian Diagnostics Group Co., Ltd. (Shenzhen Stock Exchange stock code: 300244) from May 2010 to February 2019.
Mr. Chen has been the chairman of China Medical Pharmaceutical Material Association, vice president of China Pharmaceutical Innovation and Research Development Association, chairman of Shanghai Biopharmaceutical Industry Association and vice chairman of the Shanghai Society of Genetics.
Mr. Chen obtained a bachelor degree in genetics from Fudan University in the PRC in July 1993 and a master degree of business administration from China Europe International Business School in the PRC in September 2005.